Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
75 Months -- A very good number of months - everyone would agree
My question is: Where will DCVAX - Direct be in 75 months
Even from Today Date
Cure? -- Well in my view, yes. 6 years
Rinse and Repeat -- Another 6 years +++++
And this is today's technology with DCVAX -L. 6 years
There will be improvements over time
Another statement I like to Make
Follow the DCVAX
I make sure that my children understand the potential of this Vaccine.
No matter who buys us out.
Follow the DCVAX and Invest
Don't Make Me LeaK
Anders - on the record to disagree with you.
Now are we talking in the first 3 months of approval - NO
As DCVAX helps people to whatever degree it takes them - all their family members and friends of Friends will hear about this treatment.
Everyone knows someone with a Cancer.
The message boards will be lighting up with the discussion.
Every day a new doctor will learn of the treatment.
From medical Journors or patients
There will be conferences Highlighting DCVAX, SNO - ASCO .......
It will be the talk of the town -
Nobel Peace Prize - who knows but Dr. LL deserves it.
How many people will that reach??
Now one good thing about starting slow - Production will be able to get up to speed because I think demand will pick up quicker than people think.
This is not a new aspirin LOLOLOL - I like that line
Don't Make Me Leak !
Off Topic but very interesting
Yep I didn't write the article
That author can't even spell - I was excited about the headlines.
I should just read the headlines and was excited LOLOL LOLOL
I did pick up some additional shares 15 min before the close one of the last buys at .61999 LOL
Before things light up on IHUB again I would like to say that:
People on this message board are Terrific !!!!!!
Just like someone else mentioned - I would have not stayed invested all these years if not for people here.
I can't wait to pay off someone's Pharmacy education later this year.
Lots of typo's in this story but
Currently running northbound NWBO is an exciting story developing in small caps; this little biotech is sitting on drugs in development that could potentially turn the multi-billion dollar drug-resistant cancers market upside down. NW Bio lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. NWBO has been making a number of big moves in recent days including securing new financing as well as continuing the buildout of its Sawston, UK manufacturing facility. Also, NWBO just acquired Flaskworks; a company that has developed a breakthrough system to close and automate the manufacturing of cell therapy products such as DCVax® for $4.33 million in cash and stock. We will be updating on NWBO when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with NWBO.
This is so true -
Waiting too long to be shaken out
Never thought I would be buying any more shares - loaded up to the gills
But I'm watching very closely to the end of the day.
If they try to drop it in the last 15 min - I will be there also
Were done with those .50's
Make My Day!
No Leaking here
Lunch over? - I barely finished my sandwich
That was quick ......
I'm not going to Leak today!
Anyone still think that Duffy left and went back to Merck because NorthWest didn't have anything worthwhile ???
This is fun and you're having it !!!!!!!!
Don't Make Me Leak - How cool would it be if Alice showed up here LOL
Breakthrough Automation Technology For Cell Therapy Products To Enable Scale-Up of Production Volumes and Reduction of Production Costs BETHESDA, Md., Sept. 1, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax(R) personalized immune therapies for solid tumor cancers, today announced that the Company has acquired Flaskworks, a company that has developed a breakthrough system to close and automate the manufacturing of cell therapy products such as DCVax(R). Flaskworks was previously owned by its technical founders and Corning Incorporated.
The technical team from Flaskworks has joined NW Bio as part of the acquisition. It is anticipated that the Flaskworks system will enable substantial scale-up of production volumes of DCVax products and substantial reduction of production costs. To date, the manufacture of immune cell therapies (including T cell therapies and others) has involved two major challenges. First, the manufacturing processes involve "open" steps in which the product is open to the air in the manufacturing suite. This necessitates extremely expensive "clean room" facilities with specialized infrastructure and specialized operating systems for sterile air and water, and personnel working in sterile lab suits ("space suits"). Second, the manufacturing processes are mostly manual processes -- in essence, hand crafted artisan processes by highly skilled technicians working under sterile conditions. These factors have made the manufacturing of immune cell therapies (such as T cells) very costly, and greatly limited the number of such therapies that can be produced. There simply are not enough of the specialized clean room facilities, not enough highly skilled artisan technicians, and each technician can only produce limited amounts of products. The Flaskworks system is designed to fundamentally change the manufacturing process from artisan hand work to assembly line-like automation. As such, the Flaskworks system is designed to enable the scale-up to far greater production volumes. Technicians will oversee the automated systems (potentially multiple systems per technician) rather than making the products themselves.
The Flaskworks system is also expected to significantly reduce production costs: turning "open" steps in the manufacturing process into "closed" steps, in which the product is not open to the air in the manufacturing suite, removing the need to build and operate the extremely costly clean room suites for those processes, and removing the need for personnel to work in sterile lab suits. This will greatly reduce the DCVax-L production costs. The buildout of the Sawston, UK facility has purposely been designed to proceed in phases, as modules, both for efficiency in the timing of capital costs and to allow flexibility in operations and usage. Implementation of the Flaskworks system will enable certain phases of the buildout to be simplified and streamlined. The existing manufacturing process for DCVax-L products already takes a practical and economical approach by using a batch manufacturing process combined with special cryopreservation technology. The full set of doses for a patient, for as much as 3 years of treatments, are all produced in a single 8-day manufacturing batch, and then are stored frozen in single doses. The freezing technology has been validated and was used throughout the Company's Phase 3 trial. This makes DCVax-L an off-the-shelf product for the whole treatment period after the one-time manufacturing batch, while also being a fully personalized product.
The Flaskworks system will follow the same batch-manufacturing process -- doing so in a "closed" and automated manner. Certain optimization work will be required so that the Flaskworks system will produce DCVax-L products with characteristics equivalent to the products made by the current DCVax-L manufacturing processes. This will then need to be confirmed by comparability studies. The Flaskworks technical team will work with NW Bio's contract manufacturers to accomplish this. In the meantime, the Company's DCVax products will continue to be made through the existing processes. The acquisition of Flaskworks was executed and closed on August 28, 2020. The total purchase price was approximately $4.33 million, of which $1.65 million was paid in cash at closing, up to $2.01 million will be paid in stock subject to milestone-based vesting, and $0.67 million will be paid in either cash or stock, or a combination thereof, within 120 days after the closing. The acquisition includes both intellectual property owned by Flaskworks and a license of additional intellectual property from Northeastern University. Although a number of companies have developed and are continuing to develop automated machines for certain cell therapy production processes, those machines have certain drawbacks. For example, they typically try to handle a variety of cell types and have not been optimized for a particular cell type, such as dendritic cells. In contrast, the Flaskworks system has been developed and tailored specifically for immune cells such as dendritic cells. Linda Powers, NW Bio's CEO commented, "We believe that our DCVax platform technologies are potentially applicable to all types of solid tumor cancers, which comprise the vast majority of all cancers. We are working to build the infrastructure and systems that can enable the scale-up of production to such volumes -- and can do so at a price level that will be affordable for widespread use of DCVax treatments." "The phased buildout of our Sawston, UK facility and now our acquisition of Flaskworks are major building blocks towards achieving these goals. These steps, along with others in process, have been years in the making to reach fruition at the same time as we are reaching the results of our Phase 3 clinical trial of DCVax-L for Glioblastoma." About Northwest Biotherapeutics Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax(R) dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax(R) -L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is also pursuing development of DCVax(R) -Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial, and is preparing for Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
Agree - NWBO has it covered
Sounds like she is saying yes
ATL-DC = DCVAX
But cannot come out and say it
Anything is possible nowadays ---
Many interesting Trades this afternoon
Still would like to run some Power-BI against that magical database.
Don't Make Me Leak
Interesting - Thank You for pointing this out!
The reason there wasn't any new warrants is because the company that will be buying us out already has the buyout conversion already calculated.
The Buyout price in Cash and
So many new Shares in their company.
They told Linda NO MORE WARRANTS - Take a Loan
Don't Make Me Leak
By the way: Two weeks is plenty of time to retrieve the final data reports/graphs.
All they have to do is place the new data inside of an excel format insert that excel file into their database tables and run the list of jobs to complete the process. The jobs should be READY TO GO
That's my point - The jobs should be READY TO GO
All the programming should be complete with the previous data setups.
Even with only 10% of the data retrieved the jobs should be created and tested and ready to go
I'm doing this all day with my data(work) - I'm also late with three data feeds into an outside server.
Would I love to have access to their database?
And run some PowerBI reports It would be awesome!
The Company's lead program is a 331-patient Phase III trial of DCVax(R)-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is also pursuing development of DCVax(R)-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial, and is preparing for Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
The Company currently continues to anticipate reporting topline trial data in September, and anticipates providing further updates as the process progresses.
We have news
NW Bio Announces Completion of Further Data Gathering For Phase III Trial NWBO
BETHESDA, Md., Aug. 19, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax(R) personalized immune therapies for solid tumor cancers, today announced that the remaining outstanding clinical trial data for the Company's Phase 3 trial of DCVax(R)-L for Glioblastoma brain cancer as described in the Company's last report on July 24, 2020 has now been completed by the specialty analytics firms. With this data now in hand, final quality control checking and confirmation are under way to enable Data Lock. This further data involves specialty analytics such as genomic profiling for IDH mutations and certain imaging. The independent CRO managing the trial is now integrating this data into the overall trial database containing the clinical data from the trial sites that was already complete and locked as reported on July 24, 2020, in order to complete the overall trial dataset. When Data Lock is reached, the independent statisticians will be given access to the unblinded dataset. The Company will remain blinded while the statisticians make the computations, converting the mass of raw data from the trial into formal tables and listings, and survival and progression measures, to report the trial results. As previously reported, the statisticians' work is estimated to take a couple of weeks. When their computations are completed, the Company will receive the results of those computations and thereby become unblinded. It is anticipated that the Company's Scientific Advisory Board, the Steering Committee of the Trial and other key medical expert advisors will likewise receive the results, and thereby become unblinded as well. The Company currently continues to anticipate reporting topline trial data in September, and anticipates providing further updates as the process progresses. About Northwest Biotherapeutics Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the North America and Europe. The Company has a broad platform technology for DCVax(R) dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax(R)-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is also pursuing development of DCVax(R)-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial, and is preparing for Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania. Disclaimer Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's Securities and Exchange Commission ("SEC") filings. Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company's results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws. CONTACTS Dave Innes Les Goldman 804-513-4758 dinnes@nwbio.com 240-234-0059
For those who do not watch the trades take place during the day.
We have a vast majority of trades taken place at the ASK. (Green)
And many somewhat larger trades
Please don't tell me its only .33 cents range and vol does not mean much.
Its the change from day to day that stands out
Scotty - why is the price higher than that 1 million trade if it was a dump?
Teach me Scotty -- Teach me !
I will look into it
If only investment Property - great - if true
But they must of left that off
If you sell your house today - you don't pay taxes if you purchase another property that cost more then your previous property.
you roll your gains into the next property
Nice volume today .
Now lets see the price move
Just heard that sleepy Joe will get rid of the 1031 tax credit
If you sell your home you must pay tax on your profit of your home.
you cannot roll over the profit into your new house
ugh
tax tax tax tax tax
Ok then
I'm going to the eye doctor when the market closes ...
Maybe the foot doctor too -- foot in mouth
Maybe it doesn't trade pre-market but the trade took place.
At 9:02:20 est
Between Market Makers ??
Don't Make Me Leak
Sorry - We were addressing the World Wide dominance by China
China is found in South America and Africa Draining all the resources.
Nothing New with moving in but they don't care about the people or countries
UPS preparing freezers for the Covid vaccine when its ready. (Storage)
A couple of locations.
I'm thinking we can use those facilities when we are ready ....
I think they said it can hold 600 freezers holding 40,000 vaccines
Minus 112 Fahrenheit
Netherlands and Louisville
One item that will affect us all depending on November is Capital Gains Tax. Now that is a can of Worms
That can be a discussion in itself.
She moves around I think Zambia and the countries that border
Siemens Healthineers to acquire cancer treatment company Varian for $16.4B
Deal is expected to close in the first half of 2021
BERLIN (Reuters) - German health group Siemens Healthineers said on Sunday it would acquire Varian Medical Systems Inc in a deal that values the U.S. maker of devices and software for cancer treatments at $16.4 billion.
Under the agreed transaction, Siemens Healthineers will acquire all shares in Varian for $177.50 each in cash, representing a 24% premium to the U.S. company’s closing price on Friday.
Industrial conglomerate Siemens, which spun off Healthineers in 2018 but retains a controlling stake, will provide bridge financing for the deal, which seeks to create a global leader in cancer care solutions by 2025.
"With this combination of two leading companies we make two leaps in one step: A leap in the fight against cancer and a leap in our overall impact on healthcare," said Bernd Montag, CEO of Siemens Healthineers.
I have a niece in Africa as a missionary and she gives me updates.
They are controlling all the minerals and anything else that is valuable.
They force people to work with no regards to the virus. Just fill in with the next body
First Hand Info from my Niece
Sorry if this offends anyone
I'm sure that what you say is correct
California - New York my guess
Property write offs
When policy comes out of Washington it's for the entire country and the entire economy. They can't help that taxes are higher in some states.
heck - I'm in Illinois and we are broke -- Dems running the state for years
Not the Gov but State congress spending money
Doesn't Illinois have the most gov taking that slow walk to jail LOL
Take it Down ---Who cares
If it makes you happy -
I would like you to have a great day !
Nobody is going to convince anyone of anything these days
I just wish he would come out of the basement and talk a little and take questions
LOL
No clue what your talking about
The Daily Beast ! LOLOLOLOLOL
I guess all the other Doc's behind here were Quacks also
Ok - Maybe I used the wrong wording
Jacked UP
All Im saying is that if someone gets tested 4 times they are counting it for 4 people thats it
No big deal - not even important on this board
sorry for bringing it up --- nobody is going to convince anyone of anything .
I just may know some people that can verify
Yes - Closed system - I remember that she mentioned that she was working with the best companies to achieve this... I think she said world class
Many more stories like this one coming soon !
Grateful to be a 22-year brain tumor survivor. Fortunate to get immunotherapy at UCLA! I also appreciate CRI Cancer Immunotherapy Month, including CRI's Wear White Day!
@UCLAJCCC
@CancerResearch
#immune2cancer #immunotherapy #cancer #braintumor #braincancer #gratitude #resilience
Jeannine Walston
Cancer Coach, Health & Wellness Coach, Consultant, Speaker, Integrative Expert & 21-Year Brain Tumor Survivor http://jeanninewalston.com http://healingfocus.org
Los Angeles, CaliforniaJoined July 2012
Yes for the newbies -- it was DCVAX
If that is the case Great
If not - Its not that big a deal
Lets get to the finish line PERIOD
So many years - 1 more dilution if needed then they need it
If a dilution takes place - At this point its a nothing Burger.
What this stock / vaccine can do for people is nothing short of gargantuan.
I imagine so many people hoping and praying that time go their way and able to receive this vaccine.
So yes dilution = Nothing Burger
On the stock side of things - Everyone has been given the gift to add more shares. If taken advantage of the price great if not go with the flow
Don't Make Me Leak
Anders - you have the wrong person but thats ok ---
I was so excited I forgot to open the entire article before I listed it
Don't Make Me Leak